Evaluation of HbA1c level in diabetic patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin regimen

Abstract

Abstract Background: Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) which mainly attacks the liver cells. The acute stage of the disease passes mostly without manifestations, but the chronic stage can cause hepatic fibrosis and cirrhosis, that has mostly occurred after several years. Some cirrhotic patients may develop liver failure, hepatocellular carcinoma (HCC) or fatal bleeding from esophageal or gastric varices. HCV_4 is prevalent among Middle East and Africa causing more than 80% of HCV infections and has recently spread to several European countries. In Egypt, HCV-4 responsible for almost 90% of the infections. Aim: The aim of this study is to evaluate the glycemic control in diabetic patients with chronic HCV infection after eradication of HCV by sofosbuvir plus daclatasvir with or without ribavirin regimen through HbA1c measurement before the start of treatment, at the end of treatment, and 3 months after the end of treatment.